Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04462770 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome

Name: A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome — clinical trial record (NCT04462770)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: ARGUS

StatusRecruiting

PhasePhase 3

SponsorEpygenix

Started2020-09-15

View on ClinicalTrials.gov ↗

This is a multicenter, Phase 3, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of clemizole hydrochloride (EPX-100) as adjunctive therapy in children and adult participants with Dravet syndrome (DS).

Amendment history 1 change detected by DataLookout

2026-08-14

Trial sites expanded: 60 → 69 locations

Trial Details

NCT Number	NCT04462770
Lead Sponsor	Epygenix Collaborators: Harmony Biosciences Management, Inc.
Conditions	Dravet Syndrome
Enrollment	150 participants
Start Date	2020-09-15
Primary Completion	2027-04 (estimated)
Study Completion	2029-05 (estimated)
Updated on ClinicalTrials.gov	2026-09-15